Tissue Repair Ltd (AU:TRP) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tissue Repair Ltd, listed on the ASX, reported a surge in TR Pro+® sales by 27% over the previous quarter, marking strong market acceptance with over 240 clinics placing orders. The company is advancing its TR987® treatment for chronic wounds, with significant progress in clinical trial preparations and the production of the Glucoprime® API. The company’s cash position remains robust at $15.9 million as of September 2024, despite net cash outflows driven by ongoing development and commercialization efforts.
For further insights into AU:TRP stock, check out TipRanks’ Stock Analysis page.